Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perceived gynecological efficacy of HB22
RBR-59q849Not yet recruiting
- Sponsor
- Infinant Health
- Start
- Apr 2023
- Countries
- 1
01
Overview
Open-label, single-arm trial in vaginal dryness and Noninflammatory disorder of the vagina, sponsored by Infinant Health. Primary endpoint: Perceived gynecological efficacy. Planned start Apr 2023; status: not yet recruiting.
02
Conditions
vaginal drynessNoninflammatory disorder of the vagina
Beyond the preview
Go deeper on RBR-59q849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on RBR-59q849.